Navigation Links
Intarcia Enrolls First Patients in "FREEDOM" Global Phase 3 Program for ITCA 650 in Type 2 Diabetes
Date:3/21/2013

BOSTON, March 21, 2013 /PRNewswire/ -- Intarcia Therapeutics, Inc. announced today the enrollment of the first patients in FREEDOM-1, the first of four planned Phase 3 clinical trials studying the safety and efficacy of ITCA 650 (continuous subcutaneous delivery of exenatide) for the treatment of type 2 diabetes (T2D). Intarcia is conducting the FREEDOM clinical program with strategic partner Quintiles, Inc., the world's leading clinical research organization, who will be responsible for the global implementation of all four trials. This collaboration, along with strategic input from a world-class group of renowned diabetes experts, is designed to achieve the highest standards of quality, safety and operational excellence.

(Photo: http://photos.prnewswire.com/prnh/20050301/SFTU126LOGO)

The FREEDOM clinical trial program aims to demonstrate that optimizing GLP-1 therapy with once- or twice-yearly dosing of ITCA 650 results in effective, well tolerated glycemic control that virtually ensures longer-term compliance – a transformational approach to controlling T2D that aims to free patients from the frequent self-injections that all too often result in poor therapeutic compliance and control. The FREEDOM-1 study is a placebo-controlled, double-blind study involving T2D patients whose HbA1c is not controlled on zero to three oral anti-diabetes drugs and whose HbA1c measures between 7.5% and 10.0%. The 450 patients will be randomized into three groups in a 1:1:1 ratio, evaluating ITCA 650 40 mcg/d and ITCA 650 60 mcg/d versus placebo. Subjects in the active arms will be treated with 3-month devices for the first 13 weeks that deliver an initial dose of 20 mcg/d, and then treated with 6-month ITCA 650 at doses of 40 or 60 mcg/d. The primary endpoint will be change in HbA1c at 9
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intarcia Appoints Owen Hughes Chief Business Officer and Head of Corporate Development
2. ROX Medical enrolls first UK patients in CONTROL-HTN hypertension trial at Eastbourne General Hospital
3. ROX Medical enrolls first patients in Ireland for CONTROL-HTN hypertension trial at Beaumont and Mater Private Hospitals
4. Adynxx Enrolls First Patient in Phase 2 Proof-of-Concept Study for AYX1, Lead Compound for the Prevention of Post-Surgical Pain
5. Boehringer Ingelheim Enrolls First Patients in Pivotal Phase 3 Interferon-Free Hepatitis C Trial Program
6. CalHIPSO Enrolls Over 7,700 Providers in EHR Implementation Program, Hits Other Key Milestones After First Two Years
7. PQA and CECity Launch Joint Venture to Deliver First National Pharmacy Quality Measurement, Benchmarking and Reporting Platform for Pharmacies and Health Plans
8. First Patients Dosed in Proof-of-Concept Clinical Study of Alder Biopharmaceuticals Lead Therapeutic Candidate for Treatment of Migraine, ALD403
9. Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results
10. Wyckoff Heights Medical Center Is First New York Hospital to Offer Asthmapolis Mobile Asthma Management Program
11. Quest Diagnostics Launches Dementia Diagnostic Panel, First in Industry for Treatable Forms of Cognitive Impairment Based on Medical Guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), ... the development of brachytherapy devices and medical isotopes ... it has filed a de novo ... for marketing clearance for its patented Y-90 RadioGel(TM) ... Food, Drug and Cosmetic Act (the "Act").  ...
(Date:12/24/2014)... 24, 2014 LifeScienceIndustryResearch.com ... Disposable Syringe Industry of 178 pages providing ... intelligence library. The 2014 Market ... is a professional and deep research report ... analysis, the report introduces Disposable Syringe basic ...
(Date:12/24/2014)... Ohio , Dec. 23, 2014   ... treatment decision support to healthcare providers for behavioral ... it has secured $30 million in equity financing ... Virginia C. Drosos , President and Chief Executive ... clinical adoption and development of Assurex Health,s ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4
... 2011 The CAQH® Universal Provider Datasource® (UPD®) ... as the go-to resource for complete and reliable ...  Three out of five licensed and practicing physicians ... service. About 7,000 additional providers are registering each ...
... 2011 Instrumentation Laboratory (IL) today announced the appointment ... effective May 1, 2011.  Mr. Benet began his career ... Vice President of Worldwide Marketing, Sales and Service.   ... Josep Manent who served as CEO since 1999.  Under ...
Cached Medicine Technology:900,000 Healthcare Providers Now Part of CAQH Universal Provider Datasource 2900,000 Healthcare Providers Now Part of CAQH Universal Provider Datasource 3Instrumentation Laboratory Appoints Ramon E. Benet New Chief Executive Officer 2
(Date:12/24/2014)... 2014 For nearly 20 years, June ... babies, graces, and all of life's rites of passage. ... Nancy Tupper Ling, in Toasts: The Perfect Words ... , Organized by category and containing many original ... anywhere else, this timely tome contains sayings famous and ...
(Date:12/24/2014)... December 24, 2014 Attorneys handling talcum ... an update to their website, the Talcum Powder ... between talcum powder class action lawsuits and ovarian cancer ... and ovarian cancer updates at their website, which serves ... for ovarian cancer claims are not the same as ...
(Date:12/24/2014)... Dr. Ronald Receveur, a New Albany ... dental implants in a day, has written a ... teeth-whitening treatments. , In his blog published Dec. ... writes that overusing teeth-whitening treatments can lead to tooth ... , “Because teeth-whitening treatments are available in ...
(Date:12/24/2014)... Thompson HealthDay Reporter TUESDAY, ... the experimental Ebola vaccine that U.S. officials are preparing to ... precursor of that vaccine produced a safe and potent immune ... when given to more than 100 Ugandans in 2009 and ... that could potentially protect a person against infection by Ebola, ...
(Date:12/24/2014)... -- Long-term fear of terrorists may damage your heart and ... from Israel suggests. , , Conducted by researchers from the ... Israel, the threat of war and terrorism has been a ... wanted to test whether fear of terrorism can predict an ... author Hermona Soreq, a professor of molecular neuroscience, said in ...
Breaking Medicine News(10 mins):Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 2Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 3Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 4Health News:New Albany Dentist Weighs In On New Trend of Overbleaching Teeth 2Health News:New Albany Dentist Weighs In On New Trend of Overbleaching Teeth 3Health News:Early Study Offers Hope for an Ebola Vaccine 2Health News:Early Study Offers Hope for an Ebola Vaccine 3Health News:Early Study Offers Hope for an Ebola Vaccine 4Health News:Terrorism Fears May Shorten Your Life, Study Finds 2
... make the best use of the impasse in the US over ... global //hub in that sphere, scientist and entrepreneur Dr William J ... Corp, a leading biopharma and vaccine company in the US, was ... is participating in the BioAsia 2004 summit being held there. ...
... are in terminal decline because of global warming, scientists have ... year revealed that the rate of melting across the world ... glaciers in jeopardy. ,The loss of glaciers ... of millions of people within a few decades, experts warned. ...
... A new study reports that recent decline in breast cancer ... receptor (ER)-positive tumors and women younger than 70//. ... April 2 in the Journal of Clinical Oncology (JCO). ... average age of breast cancer diagnosis is 62. ...
... she wrote it off as just a part of growing ... month// .” ,“I was increasingly having painful menstrual ... 43. ,After running some tests, her doctor discovered ... in 10 women, usually of childbearing age. In addition to ...
... being led to believe that, if they get circumcised, ... a ‘vaccine;’ but it is not a vaccine// and ... false pretenses. ,“The century-old circumcision ‘experiment’ in ... Africa be any different?” asks Dan Bollinger, director of ...
... Prime Minister Girija Prasad Koirala who, despite his indifferent health ... coming to the SAARC summit. ,Addressing the opening ... statesman of Nepal, also used the occasion to confess to ... gambled 60 years of my political career to have a ...
Cached Medicine News:Health News:India Should Take the Lead in Stem Cell Research, Expert 2Health News:Bolivian Glacier Melts, Dangerously Fast 2Health News:Breast Cancer? ER Positive or Negative 2Health News:Hope for Ending the Pain, Infertility of Endometriosis? 2Health News:Hope for Ending the Pain, Infertility of Endometriosis? 3Health News:Promoting Circumcision to Prevent HIV is Misguided and Will Backfire: ICGI 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: